Category Archives: Neuroscience

Neuroscience Antibodies and Assays Market- Roadmap for Recovery From COVID-19 | Technological Advances to Boost the Market Growth | Technavio -…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the neuroscience antibodies and assays market and it is poised to grow by USD 1.36 bn during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abcam Plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., GenScript Biotech Corp., Merck KGaA, Rockland Immunochemicals Inc., Santa Cruz Biotechnology Inc., Tecan Group Ltd., and Thermo Fisher Scientific Inc. are some of the major market participants. The technological advances will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Neuroscience Antibodies and Assays Market 2020-2024: Segmentation

Neuroscience Antibodies and Assays Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40305

Neuroscience Antibodies and Assays Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The neuroscience antibodies and assays market report covers the following areas:

This study identifies advances in neuroscience instruments as one of the prime reasons driving the neuroscience antibodies and assays market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Neuroscience Antibodies and Assays Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DRIVERS AND CHALLENGES

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

PART 12: VENDOR ANALYSIS

PART 13: APPENDIX

PART 14: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

More:
Neuroscience Antibodies and Assays Market- Roadmap for Recovery From COVID-19 | Technological Advances to Boost the Market Growth | Technavio -...

Latest News:: Neuroscience Market Product and Application Segmentation and Strategies with Forecast till Period, 2020-2025| GE Healthcare, Siemens…

Global Neuroscience Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)

Chicago, United States: The global Corona impact on Neuroscience Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Neuroscience market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Neuroscience market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Neuroscience market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Neuroscience market.

Leading players of the global Neuroscience market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Neuroscience market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Neuroscience market. It also provides useful recommendations for new as well as established players of the global Neuroscience market.

Neuroscience Market competition by top manufacturers/Key player Profiled:GE Healthcare, Siemens Healthineers, Noldus Information Technology, Mightex Bioscience, Thomas RECORDING GmbH, Blackrock Microsystems, Tucker-Davis Technologies, Plexon, Phoenix Technology Group, NeuroNexus, Alpha Omega

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2298403

The report attempts to offer high-quality and accurate analysis of the global Neuroscience Market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Neuroscience market that are impacting their business. Readers can become aware of crucial opportunities available in the global Neuroscience market as well as key factors driving and arresting market growth. The research study also provides deep geographical analysis of the global Neuroscience market and sheds light on important applications and products that market players can focus on for achieving strong growth.

the Global Neuroscience Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Neuroscience market, the market size and growth, as well as the major market participants.The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Segmentation by Product:

Whole Brain ImagingNeuro-MicroscopyElectrophysiology TechnologiesNeuro-Cellular ManipulationStereotaxic SurgeriesAnimal BehaviorOthers

Segmentation by Application:

HospitalsDiagnostic LaboratoriesResearch InstitutesOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2298403

Highlighted points of the global Market research report:It includes global market driving and restraining factorsIt offers business profiles of various global investorsAnalysis of micro and macro-economic factors impacting on the global market

Regional analysis covers:

1.North America (USA, Canada and Mexico)2.Europe (Germany, France, UK, Russia and Italy)3.Asia-Pacific (China, Japan, Korea, India and Southeast Asia)4.South America (Brazil, Argentina, Columbia etc.)5.Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Why Report Hive Research:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Touch With Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Read the original post:
Latest News:: Neuroscience Market Product and Application Segmentation and Strategies with Forecast till Period, 2020-2025| GE Healthcare, Siemens...

AbbVie Receives Orphan Drug and Fast Track Designations from the US Food and Drug Administration for Elezanumab, an Investigational Monoclonal…

NORTH CHICAGO, Ill., Sept. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord injury.

Elezanumab is a monoclonal antibody of the human immunoglobulin (Ig)G1 isotype that binds selectively to repulsive guidance molecule A (RGMa). RGMa is an inhibitor of axonal outgrowth and recognized as an important factor in inhibiting neuronal regeneration and functional recovery following central nervous system (CNS) damage. Elezanumab is being investigated to treat spinal cord injuries,multiple sclerosis and acute ischemic stroke. It is currently in a phase 2 study (NCT04295538) for the treatment of spinal cord injury.

"AbbVie is committed to delivering therapies that make a meaningful difference in patients' lives," said Michael Gold, MD, Vice President, Neuroscience Development. "Spinal cord injuries result in devastating lifelong physical, emotional and economic consequences. The FDA's Orphan Drug and Fast Track Designation for spinal cord injury patients signals an important step forward in AbbVie's ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients."

Innovative Partnerships for Spinal Cord Injury PatientsCurrently AbbVie is partnering with the Shirley Ryan AbilityLab, a global leader in physical medicine and rehabilitation, and MC10, a health digital solutions company, in a pilot study involving 20 spinal cord injury patients. The pilot study will inform the ongoing Phase 2 study of elezanumab by testing optimal biosensor placement to capture surface electromyography (sEMG), among other assessments. The pilot study will be completed in approximately two months.

AbbVie is also partnering with United Spinal Association and the North American Spinal Cord Injury Consortium to support spinal cord injury awareness and incorporate spinal cord injury community perspectives into our clinical research and outreach.

About Spinal Cord InjuryA spinal cord injury often causes permanent changes in motor function, sensation and other body functions below the site of the injury.3Cervical spinal cord injuries are the most common and debilitating, with many occurring in younger people, typically male adults, with 43 as the average age at the time of injury.4A spinal cord injury after age 65 is most often caused by a fall.5Signs and symptoms of spinal cord injuries include loss of movement; loss of sensation, including the ability to feel heat, cold and touch; loss of bowel or bladder control; exaggerated reflex activities or spasms; changes in sexual function, sexual sensitivity and fertility; pain or an intense stinging sensation caused by damage to the nerve fibers in the spinal cord; and difficulty breathing, coughing or clearing secretions from lungs.6

About Orphan Drug and Fast Track Designations Orphan Drug Designation is given to a drug or biologic for the treatment, diagnosis or prevention of a rare disease or condition.7The FDA uses a fast track process to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.8

About the Shirley Ryan AbilityLabShirley Ryan AbilityLab, formerly the Rehabilitation Institute of Chicago (RIC), is the global leader in physical medicine and rehabilitation for adults and children with the most severe, complex conditions from traumatic brain and spinal cord injury to stroke, amputation and cancer-related impairment. The organization expands and accelerates leadership in the field that began at RIC in 1953. The quality of its care and research has led to the designation of "No. 1 Rehabilitation Hospital in America" byU.S. News & World Reportevery year since 1991. The organization offers three clinical service lines: inpatient rehabilitation for those requiring complex medical and nursing care, intensive Day Rehabilitation in an outpatient setting, and Outpatient therapy and physician consultation services. Upon opening in March 2017, the $550 million, 1.2-million-square-foot Shirley Ryan AbilityLab became the first-ever "translational" research hospital in which clinicians, scientists, innovators and technologists work together in the same space, surrounding patients, discovering new approaches and applying (or "translating") research real time. This unique model enables patients to have 24/7 access to the brightest minds, the latest research and the best opportunity for recovery.Shirley Ryan AbilityLab is a 501 (c)(3) nonprofit organization. For more information, go to http://www.sralab.org.

About MC10MC10 is a privately held company focused on improving human health through digital solutions. The company combines conformal BioStamp sensors with clinical analytics to unlock novel insights from physiological data collected from the home or in clinical settings. Our flagship product, BioStamp nPoint, isintended forthe clinical research community. MC10 is headquartered in Lexington, MA. Visit MC10 online at mc10inc.comor follow us on LinkedIn.

About United Spinal AssociationUnited Spinal Association is the largest non-profit organization dedicated to enhancing the quality of life of all people living with spinal cord injuries and disorders (SCI/D), including veterans, and providing support and information to loved ones, care providers and professionals. United Spinal has over 70 years of advocacy experience educating and empowering wheelchair users impacted by paralyzing conditions and mobility disabilities to achieve and maintain the highest levels of independence, health and personal fulfillment. United Spinal has over 50,000 members, 54 chapters, close to 200 support groups and more than 100 rehabilitation facilities and hospital partners nationwide. United Spinal Association is also a VA-recognized veterans service organization (VSO) serving veterans with disabilities of all kinds. Resources United Spinal provides include a Pathways to Employment (PTE)program, Accessibility Services Consultingaiding ADA compliance and accessibility, a virtual Resource Center and AskUs service offering personalized peer support, andNew Mobility magazine, a premier disability lifestyle publication. The organization's headquarters is in Kew Gardens, NY with a government relations office in Washington, DC. https://unitedspinal.org/

About the North American Spinal Cord Injury Consortium (NASCIC)The North American Spinal Cord Injury Consortium (NASCIC) has a focus to build collaboration and a unified voice among the spinal cord injury community, mainly those living with the condition and those organizations that represent them, within North America.

About Elezanumab (ABT-555)Elezanumab is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries,multiple sclerosis and acute ischemic stroke.

About AbbVie in Neuroscience At AbbVie, our commitment to preserve the personhood of those living with neurologic and psychiatric disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie's Neuroscience portfolio consists of approved therapies and a robust pipeline in neurologicand psychiatric disorders, including Alzheimer's disease,bipolar disorder and depression, major depressive disorder, migraine, multiple sclerosis, Parkinson's disease,post-stroke spasticity, schizophrenia, and stroke.

We have a strong investment in neuroscience research, with our Foundational Neuroscience Center inCambridge, Massachusetts, and our Neuroscience Discovery site in Ludwigshafen,Germany, where our research and perseverance in these challenging therapeutic areas is yielding a deeper understanding of the pathophysiology of neurologic diseases, and identifying targets for potential disease-modifying therapeutics aimed at making a difference in people's lives. For more information, please visitwww.abbvie.com.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie on Twitter,Facebook,Instagram,YouTubeandLinkedIn.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

View original content:http://www.prnewswire.com/news-releases/abbvie-receives-orphan-drug-and-fast-track-designations-from-the-us-food-and-drug-administration-for-elezanumab-an-investigational-monoclonal-antibody-rgma-inhibitor-for-the-treatment-of-spinal-cord-injury-301138702.html

SOURCE AbbVie

Read the original post:
AbbVie Receives Orphan Drug and Fast Track Designations from the US Food and Drug Administration for Elezanumab, an Investigational Monoclonal...

Neuroscience Market: Recent Industry Trends and Projected Industry Growth, 2019-2029 – The Daily Chronicle

A new report by XploreMR takes a deep dive into the Aquaculture Feed and Pharmaceuticals Market after conducting meticulous research, assessing each microscopic aspect of the market. The researches have connected the dots with minuscule details that shape into an intricate, immaculate yet elucidate study. The report presents a thoroughly scrutinized study of the Aquaculture Feed and Pharmaceuticals Market, leaving no stone unturned in offering market players a valuable and constructive tool that navigates them in the profitable path with the right set of objectives.

Following the methodology of Porters Five Forces analysis, the report emphasizes macro concepts such as the threat of new entries in the Aquaculture Feed and Pharmaceuticals Market, supplier power, threat of substitution, and buying power. Dwelling deeper into each of the factors, details about the competitive landscape, strategies of leading market players, and changes in the landscape, are also analyzed. In addition to competitive analysis, the researchers have also employed PESTEL analysis to study the impact of political, economic, social, technological, environmental, and legal factors on the keyword, thus leaving no loose ends.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/4949

The researchers have studied the factors that are expected to drive the growth of the Aquaculture Feed and Pharmaceuticals by creating revenue opportunities, directly and indirectly. Similarly, the emerging trends, both long-term and short-term, present factors that are likely to impact the markets growth and project the direction the whole market is moving. Economical, technological, or any other trend that could bestow opportunities, have been studied. Moreover, the researchers have expanded the analysis beyond growth prospects and analyzed the possible restraining factors to the growth of the Aquaculture Feed and Pharmaceuticals Market, thus enabling market players to foresee the likely challenges and emerge successful through the forecast period 2019-2029.

In addition to the macro-economic factors that drive the global market, the market divulges micro-economic factors, diving into each individual segment such as geographical, end-use segments, and products, among others, and studies each of the segments with respect to different geographies. The geography-specific insights paint a crystal clear picture of the growth of every individual segment studied in the report, thereby enabling regional market players to leverage the trends in the region.

The report assesses key players in the Aquaculture Feed and Pharmaceuticals Market, studying their services, strategies, landmarks, growth plans, and recent developments. By studying multiple organizations covering small, medium, and large players the report enables emerging players to equip themselves with knowledge of competition scenarios. The most critical aspect in the competitive landscape individual growth strategy is studied extensively by dwelling into the foregoing growth trajectory of the organization. Moreover, the study paints a picture of the individual standpoints of the players in the years to come, considering the drivers and trends.

To breakdown the vast study that spreads through geographies, products, and end-use segments, among other market-specific segments, the authors present CAGR (Compound Annual Growth Rate) of each segment throughout the years of forecast. CAGR is a simplistic representation of growth that clearly projects which segment registered the highest/least growth through the forecast period 2019-2029. Moreover, each segment is analyzed on the basis of volume and volume, also projected with year-on-year growth and CAGR.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/4949

Researchers also present production and consumption analysis, key findings, important suggestions and recommendations, and other aspects, thus offering a comprehensive picture of the Aquaculture Feed and Pharmaceuticals Market to bolster market players in planning their strategies in the years to come.

Important Questions Answered

Highlights of TOC:

Overview: Presents a broad overview of the Aquaculture Feed and Pharmaceuticals market, acting as a snapshot of the elaborate study that follows.

Market Dynamics: A straight-forward discussion about key drivers, restraints, challenges, trends, and opportunities of the Aquaculture Feed and Pharmaceuticals market.

Product Segments: Explores the market growth of the wide variety of products offered by organizations, and how they fare with end-users.

Application Segments: This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Aquaculture Feed and Pharmaceuticals market.

Geographical Segments: Each regional market with a region-specific study of each segment- is carefully assessed for understanding its current and future growth scenarios.

Company Profiles: Leading and emerging players of the Aquaculture Feed and Pharmaceuticals Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Get Full Report Access athttps://www.xploremr.com/cart/4949/SL

Why Do Companies Trust XMR?

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis

Contact us:

XploreMR

111 North Market Street, Suite 300,

San Jose, CA 95113, United States

Ph.No: +16692840108

E-mail id- [emailprotected]

Web: https://xploremr.com

View original post here:
Neuroscience Market: Recent Industry Trends and Projected Industry Growth, 2019-2029 - The Daily Chronicle

Brain Machine Interfaces and Neuromodulation Market will touch a new level in upcoming year with Top Key Players like Advanced Bionics, Advanced Brain…

Brain Machine Interfaces and Neuromodulation Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Brain Machine Interfaces and Neuromodulation Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=266689

Top Key Players Profiled in This Report:

Advanced Bionics, Advanced Brain Monitoring, BIOS, Bitbrain, BrainCo, Cochlear Limited, Cognixion, Dreem, Emotiv, Flow Neuroscience, Halo Neuroscience, InteraXon, MED-EL, Neurable, Neuralink, NeuroPace, Neuros Medical, NeuroSky, Nextmind, Paradromics, Synchron, Thync, Versus

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Brain Machine Interfaces and Neuromodulation market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Brain Machine Interfaces and Neuromodulation markets trajectory between forecast periods.

For extensive comprehension of market dynamics, the Brain Machine Interfaces and Neuromodulation Market is bifurcated among various regions:

Years considered for this report:

Get Up to 20% Discount on this Premium Report:

https://www.a2zmarketresearch.com/discount?reportId=266689

The report gathers the essential information including the new strategies for growth of the industry and the potential players of the global Brain Machine Interfaces and Neuromodulation Market. It enlists the topmost industry player dominating the market along with their contribution to the global market. The report also demonstrates the data in the form of graphs, tables, and figures along with the contacts details and sales of key market players in the global Brain Machine Interfaces and Neuromodulation Market.

Reasons for buying this report:

Table of Contents

Global Brain Machine Interfaces and Neuromodulation Market Research Report 2020 2026

Chapter 1 Brain Machine Interfaces and Neuromodulation Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Brain Machine Interfaces and Neuromodulation Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=266689

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Read more:
Brain Machine Interfaces and Neuromodulation Market will touch a new level in upcoming year with Top Key Players like Advanced Bionics, Advanced Brain...

Mapping the terra incognita of our brains – Pursuit

The most evolutionarily ancient part of our brain is the part that we know the least about.

The human subcortex is located deep in the brains centre and processes everything from our basic senses to long-term memories.

Dysfunction of the subcortex is associated with numerous brain and mental health disorders, including Huntingtons and Parkinsons diseases, schizophrenia and depression.

Our new research, published in Nature Neuroscience, unveils a new brain atlas of the human subcortex, revealing an astoundingly complex hierarchical structure and 27 new subcortical regions.

Brain cartography is the age-old science of map-making for the brain.

Read more

Since the 19th century, brain cartographers have mostly focussed on mapping the territories, regions and networks of the outermost layer of the human brain, known as the cerebral cortex.

This has left the subcortex as an uncharted terra incognita.

As a result of this scarcity of subcortical atlases, many attempts to derive a wiring diagram for the brain, known as the human connectome, often exclude the subcortex.

Furthermore, selecting the best location for focal therapies targeting the subcortex like deep brain stimulation (DBS) requires detailed subcortical atlases to enable accurate targeting.

This involves implanting electrodes into a patients brain and electrically stimulating subcortical targets to treat the symptoms of Parkinsons disease, epilepsy and several neuropsychiatric disorders.

Identifying stimulation targets can be challenging without an atlas.

Our team used high-resolution functional magnetic resonance imaging (MRI) scans of more than 1000 people to map the most detailed subcortical atlas to date.

Our research team discovered 27 new territories of the human subcortex, each demarcated by distinct borders and associated with a distinct function.

Read more

But our new atlas reveals an astoundingly complex organisational architecture that stretches across four hierarchical levels.

Amazingly, the borders separating some of the areas shifted when people were asked to engage in cognitively demanding tasks during the brain scan.

It means that these territories and regions of the subcortex are dynamic and can reorganise depending on an individuals actions and thoughts.

The new atlas represents several years of work to map the functional areas of one of the remaining unchartered territories of the human brain.

The atlas, which was made possible by the high-quality brain scans provided by the Human Connectome Project, was initially mapped using brain scans from a 3 Tesla MRI scanner this is the type of scanner typically found in most hospital radiology departments.

Our research used a high-field strength 7 Tesla scanner to reproduce the atlas revealing new areas in unprecedented detail.

Crucially, the subcortical atlas provides neuroscientists with new opportunities to study the function of the brains subcortex in health and disease.

Just as atlases of the world were vital to the circumnavigators of the past, atlases of the brain are also vital to neurosurgeons navigating the subcortex to implant electrodes for deep brain stimulation (DBS) and other targeted treatments.

Read more

Whereas circumnavigators relied on sextants and hand-drawn maps, modern brain cartography utilises brain MRI scans and advanced computational techniques.

That said, the basic principles are more or less the same and involve drawing boundaries at locations of abrupt change in brain structure and patterns of connectivity.

The unprecedented resolution of the new subcortical atlas can assist delivery of targeted treatments to highly specific subcortical territories.

The atlas is currently used to identify treatment targets in our ongoing clinical trial of a novel transcranial magnetic stimulation (TMS) therapy for obsessive-compulsive disorder (OCD).

OCD is associated with brain changes in a key region of our atlas that is called the striatum, and so we aim to target TMS therapy to cortical regions that are strongly connected to this region.

Without an accurate map, targeting of TMS and other precision therapies can be challenging, if not impossible.

Notably, the subcortex is the brains central gatekeeper, modulating input and output information between the outer layers of the brain and the rest of the body.

Read more

Our atlas reveals how specific regions and territories of the subcortex are connected to the rest of the brain and form brain-wide networks that orchestrate everything from cognitive function to sensory and motor processing.

While the subcortex is spatially distant from the outer layers of the brain, we found that each of the 27 newly-discovered subcortical territories display patterns of activity that are highly synchronised with specific parts of the cerebral cortex.

It demonstrates the extent to which different parts of the brain are interconnected to form networks.

Our new atlas maps an important and previously unchartered part of the human brain in unprecedented detail, but it also reveals just how much we have yet to learn about the complexities of our brains.

Banner: Erasmus Wilson/Wellcome Trust

Read the original post:
Mapping the terra incognita of our brains - Pursuit

Area 32 How the Brain Balances Emotion and Reason – SciTechDaily

Area 32 balances activity from cognitive and emotional brain areas in primates.

Navigating through life requires balancing emotion and reason, a feat accomplished by the brain region area 32 of the anterior cingulate cortex. The area maintains emotional equilibrium by relaying information between cognitive and emotional brain regions, according to new research in monkeys published inJNeurosci.

Emotional balance goes haywire in mood disorders like depression, leading to unchecked negative emotions and an inability to break out of rumination. In fact, people with depression often have an overactive area 25, a region involved in emotional expression. Healthy emotional regulation requires communication between cognitive regions, like the dorsolateral prefrontal cortex (DLPFC), and emotion regions, like area 25, also known as the subgenual cortex. But because these two areas are weakly connected, there must be a middleman involved.

Superficial layer neurons from the DLPFC send feedforward projections to the deep layers of A32. A32 sends projections to A25 originating in superficial and deep layers of A32. By predominantly targeting disinhibitory neurons in the superficial layers, pathways from A32 to the superficial layers of A25 may allow excitatory signals to propagate through the local circuitry. By predominantly targeting PV neurons in the deep layers, A32 engages a stronger inhibitory system and likely has a stronger ability to dampen activity in the local circuitry. Credit: Joyce et al., JNeurosci 2020

Joyce et al. used bidirectional neuron tracers to visualize the connections between the DLPFC, area 25, and area 32, a potential middleman, in rhesus monkeys. The DLPFC connects to the deepest layers of area 32, where the strongest inhibitory neurons reside. Area 32 connects to every layer of area 25, positioning it as a powerful regulator of area 25 activity. In healthy brains, the DLPFC signals to area 32 to balance area 25 activity, allowing emotional equilibrium. But in depression, silence from the DLPFC results in too much area 25 activity and out-of-control emotional processing.

Reference: Serial Prefrontal Pathways Are Positioned To Balance Cognition and Emotion in Primates 28 September 2020, Journal of Neuroscience.DOI: 10.1523/JNEUROSCI.0860-20.2020

Originally posted here:
Area 32 How the Brain Balances Emotion and Reason - SciTechDaily

Want to Decode the Human Brain? There’s a New System for That, and It’s Pretty Wild – Singularity Hub

Even for high-tech California, the man strolling around UCLA was a curious sight.

His motion capture suit, sensor-embedded gloves, and virtual reality eyewear were already enough to turn heads. But what stopped people in their tracks and made them stare was a bizarre headgear, tightly strapped to his head through a swimming cap-like device embedded with circular electrode connectors. Several springy wires sprouted from the headgearpicture a portable hard drive hooked up to a police siren enclosureand disappeared into a backpack. The half-cyborg look teetered between sci-fi futurism and hardware Mad Libs.

Meet Mo-DBRS, a setup that could fundamentally change how we decode the human brain.

The entire platform is a technological chimera that synchronizes brain recordings, biomarkers, motion capture, eye tracking, and AR/VR visuals. Most of the processing components are stuffed into a backpack, so that the wearer isnt tethered to a landline computer. Instead, they can freely move around and exploreeither in the real world or in VRsomething not usually possible with brain scanning technology like MRI.

Movement may seem like a trivial addition to brain scanning, but its a game changer. Many of our treasured neural capabilitiesmemory, decision-makingare honed as we explore the world around us. Mo-DBRS provides a window into those brain processes in a natural setting, one where the person isnt told to hold still while a giant magnet clicks and clangs around their head. Despite its non-conventional look, Mo-DBRS opens the door to analyzing brain signals in humans in environments close to the real world, while also having the ability to alter those brain signals wirelessly with a few taps on a tablet.

All custom software powering Mo-DBRS is open-sourced, so neuroscientists can immediately play with and contribute to the platform. However, because the setup relies on volunteers with implanted electrodes into the brain, its currently only tested in a small number of people with epilepsy who already have neural implants to help diagnose and prevent their seizures.

Published in Neuron last week, the response from the neuroscience community on Twitter was a unanimous Wow! Fantastic work, wrote Dr. Michael Okun, Medical Director at the Parkinsons Foundation. Very impressive setup, tweeted Dr. Klaus Gramann, a researcher in mobile brain-body imaging at Technische Universitt Berlin.

Dreamt since grad school of 1-day being able to record from deep brain regions (like hippocampus) in humans during spatial navigation & learning/memory in naturalistic experiences, tweeted lead author Dr. Nanthia Suthana at UCLA. My lab team has made that dream come true!

Mo-DBRS isnt as sleek as Neuralinks brain implant. Its also restricted to people with electrodes already in their brains. So whats the big deal?

Everything. Those sci-fi dreams of restoring memory, reversing paralysis, battling depression, erasing fear, and solving consciousness? They all depend on capturing and understanding the human brains neural codethat is, how do electrical firings turn into memories, emotions, and behavior? Since the beginning of modern neuroscience, this has been done using electrodes implanted into mice or other experimental animals.

Take memory, a brain capability that lays the foundation of who you are.

Until now, memory research has mostly relied on rodents scurrying around mazes looking for tasty treats. Rough translation? Those experiments simulate us finding our cars in a parking lot, and identify the brain waves behind that spatial memory. By recording signals from the mices hippocampi, a seahorse-shaped structure buried deep inside the brain, scientists have set up a framework of how our memory workshow a single experience is tied to a time and space, and how a precious memory is linked to our emotions and reinforced.

The obvious problem? Humans arent mice.

For a brain function as intimate as memory, its incredibly difficult to extrapolate from rodent brain recordings. While traditional brain imaging methods for humans, such as functional MRI (fMRI) or magnetoencephalography (MEG) can paint a stationary image of the brain as it remembers a placeoften played on a video screenthe setup is far from normal in that the person is completely immobile.

Mo-DBRS goes after a whole wish list of brain decoding needs: reading and writing from the human brain in real time, wirelessly, while the person walks around, and combining neural recordings with heart rate, breathing, and other biomarker sensors.

The inspiration came from patients with epilepsy and other neurological disorders who already have electrodes implanted into their brains and go about their normal lives. There are over 2,000 individuals with chronic sensing and stimulation deviceswith the number expected to increase as additional invasive treatments are proven successful, the team wrote. These devices are implanted into deep regions of the brainthose controlling memory, emotion, and movement. With careful planning to avoid interfering with their treatment, the authors reasoned, its possible to tap into these neural recordings to directly decode the human brains activity in a real-life setting, rather than relying on rodent studies or MRI-style immobile brain imaging.

The heart of Mo-DBRSs brain recording and stimulation setup is a medical device called NeuroPace, which is often implanted inside the skull to help epilepsy patients control their seizures. Think of NeuroPace as a pacemaker for the brain. It can both read the brains electrical signals and write into the brainusing short electrical pulses to prevent a seizure electrical storm from occurring. However, like a radio, many brain processes rely on a certain frequency. By skirting the frequencies that help control seizures, the team was able to listen in and control other brain processes, such as electrical signals that form as people explore new environments. Data from the implanted device is wirelessly transferred to a custom-built wand (the weird hard drive-police siren-looking thing) strapped to the outside of the head.

Using a Raspberry PI computer and a tabletboth stored inside a backpackthat are connected to the wand, the team was able to wirelessly program the neural implant to deliver electrical pulses into the brain. At the same time, the team also added scalp EEG, which measures the brains electrical waves through electrodes embedded in a cap thats worn on the head like a swim cap. This technological tag-team provides an explosion of neural data, from both inside and outside the brain.

Moving beyond the brain, the team further equipped volunteers with a chest strap that senses heart rate, breathing, and sweating. These biomarkers capture the emotional responses around a specific memory, which could help better understand how emotionally-charged memories tend to stick around. To synchronize all the data, the team added an artificial marking signala strange-looking electrical patterninto brain recordings to denote the start of an experiment.

The whole system weighs about nine pounds, with most of the processing components tucked inside a backpack. A lighter version weighing about a pound, called Mo-DBRS Lite is also ready to go, the team explained, but comes with the caveat of decreased efficiency on synchronization with a higher delay in reading from the brain.

As a proof-of-concept, Mo-DIBS was tested on seven volunteers already implanted with the NeuroPace system. One person easily walked around a room to look at a wall-mounted sign while having his eyes, brain activity, and other biomarkers tracked without a hitch. Add in a component of VR, and its completely possible to recreate the classic memory experiment of navigating a mazeonly this time, rather than rodents, scientists are recording directly from the human brain, with the potential to disrupt those signals and play with memory.

Although Mo-DBRS is built using NeuroPace, the platform can be integrated with other existing neural implants, the team said. The entire software code is open-sourced for researchers to collaborate and expand on.

Theres a lot of potential here with the platform to start asking questions that we havent been able to do before in neuroscience, because weve been limited by the immobility of our participants, said Suthana. We can start to explore novel therapies that involve neurostimulation and [understand] the neural mechanisms that are involved in these types of treatments.

Image Credit: christitzeimaging.com/Shutterstock.com

Read more here:
Want to Decode the Human Brain? There's a New System for That, and It's Pretty Wild - Singularity Hub

COVID-19 Ushers in the Future of Conferences – The Scientist

The Society for Mathematical Biology and the European Society for Mathematical and Theoretical Biology had planned to hold a joint conference this August in Heidelberg, Germany. But by the time spring rolled around, and the pandemic took firm hold of global travel, that was looking less and less likely. On May 9, the organizers postponed the in-person meeting until 2021. Amber Smith, a mathematical biologist at the University of Tennessee Health Science Center, and her fellow conference organizers stepped in to put together a virtual conference to give researchers a chance to share the research still advancing worldwide.

We were really trying to have a meeting that was as close to an in-person meeting as we could possibly have, Smith tells The Scientist. They found Sococo, a platform that allows users to create an online building. The organizers worked closely with virtual event coordinators at MathDept.org to design the Sococo virtual space so it would provide for socializing, networking, and mentoring, as well as hearing talks, seeing posters, and visiting the meetings corporate sponsors.

The goal, according to Smith, was to build an experience that was more than sitting on a Zoom call watching talk after talk. Participants, represented by little colored dots, entered a room by clicking on it and socialized using a feature that finds and pings colleagues for a video chat within the Sococo platform. Via Zoom and webinar integration, all the people in a virtual presentation space attended the same talks and could ask questions by chat, audio, or video.

We got a ton of feedback from people saying that they absolutely loved it, Smith says. Plus, the roughly 1,800 attendees represented more than 90 different countriestwo to three times as many as at previous in-person Society for Mathematical Biology meetings. The organizers plan to incorporate some virtual components into future conferences, even post-pandemic, she adds.

If we could do it for coronavirus, then we can do it for the climate crisis, too.

Abraham Palmer, University of California, San Diego

Plenty of meetings have gone virtualor been canceled all togethersince the beginning of the COVID-19 pandemic. Proponents of online conferences point to reduced carbon emissions and increased accessibility as they make the case for making many of the pandemic-induced changes to meetings permanent. It remains to be seen whether connections made online will support science in the same way as those made in person, but researchers around the world are trying out strategies to make virtual interactions a success.

Even before the pandemic forced the issue, scientists had been thinking about ways to reduce their carbon footprints, often by cutting back on air travel.

Between the record number of hurricanes in the Atlantic and fires in the western US, there is an urgent climate emergency, Abraham Palmer, a geneticist at the University of California, San Diego, tells The Scientist. He and Chloe Jordan of the National Institute on Drug Abuse wrote an editorial published on September 16 touting the climate benefits of virtual meetings and exhorting scientists to act. In a comment published August 13, Palmer and Jordan describe how well an online planning meeting for the annual American College of Neuropsychopharmacology conference worked, while detailing the high costboth in finances and CO2 emissionsof flying everyone to previous planning sessions.

Participants video chatting in the Sococo platform at the Society for Mathematical Biology meeting held online in August

AMBER SMITH

Meeting online, whether its for a conference, study section, or worldwide lab gathering, works better than people expect, and its more convenient and economical, Palmer says. When colleagues talk about missing the in-person stuffdinners, drinks, and chance meetings when sharing a cab to or from an airporthe reminds them of the climate, financial, and time burden of all of those things that theyre missing and of the benefits of changing things up.

I really do hope that were going to look back in five or ten years and this will really have been a turning point where a lot of the things that we had leading up to COVID are never going to get rebuilt the same way they were, he says. If we could do it for coronavirus, then we can do it for the climate crisis, too.

Another benefit of meeting virtually is how many more people can access the conferences. Researchers with caregiving responsibilities, disabilities, travel restrictions, scheduling conflicts, or limited funds are more likely to be able to attend a meeting online, says Sarvenaz Sarabipour, a computational biologist at Johns Hopkins University. She and an international group of other early-career researchers posted a preprint on bioRxiv in April in which they curated a database of more than 270 past in-person conferences across scientific disciplines and evaluated them for inclusivity and sustainability.

They found that nearly 860,000 people spent more than $1.288 billion and generated upwards of 2 million tons of CO2 attending these conferences between 2016 and 2020. And for the most part, the gatherings had no public diversity or gender equity policies and didnt offer childcare or formal accommodations for nursing a baby. The authors propose several alternatives, including taking things online and putting emphasis on regional conferences or coordinating several hubs of one larger conference, so less air travel would be required to attend, an idea that Palmer favors as well.

One of the main objections that people make to virtual meetings is the loss of networking time, especially for early-career researchers looking for jobs. That criticism is unfounded, according to Sarabipour, who says that the websites of scientific journals, Twitter, and, more recently, massive Slack communities of early-career scientists have been more consistent sources for jobseekers than once-yearly scientific meetings. And despite the objections, the widespread adoption of online interactions during the pandemic begs the question of why we had to get to this point to do something this good. Sarabipour says.

Even before the pandemic, some researchers were working on making meetings better. Last summer, Dan Goodman, a computational neuroscientist at Imperial College London, was involved in discussions with various colleagues about how to reduce the climate impact of conferences. People were saying we should make them online, and I was very skeptical of that, because I understood that the point of conferences is not just to look at the talks, its to meet people and to make new connections, he tells The Scientist. I wasnt really convinced that it would work online.

One of the main objections that people make to virtual meetings is the loss of networking time, especially for early-career researchers looking for jobs.

Then, in September 2019, Goodman headed to the Conference on Cognitive Computational Neuroscience in Berlin, where he participated in a so-called mind matching session. Participants provided three abstracts representative of their research and were matched by an algorithm with up to six other scientists, with whom they had 15-minute conversations.

My mind was absolutely blown by it, because I sat down, and I met six people that Id never met before. Two of them were working on exactly the same problem that I was working on, and Id never heard of them, Goodman says. I thought, Okay, if you have something as powerful as this, maybe you can get rid of in-person conferences because you can replace that social element, which is the point of the whole thing.

Goodman got in touch with University of Pennsylvania computational neuroscientist Konrad Kording and Titipat Achakulvisut, a graduate student in Kordings group who led the development of the algorithm behind the mind matching. It works by analyzing the text supplied by each person, as well as people they already know and people they hope to meet, and using those analyses to create a matrix of compatibility from which they pull possible matches. They use a similar strategy for matching jobseekers with job listings at meetings.

Along with some other colleagues, Goodman, Kording, and Achakulvisut started to plan an online computational neuroscience unconference called neuromatch that, in addition to having live talks via Crowdcast, would offer attendees six suggestions of people to speak to. When things started to shut down due to COVID-19, they quickly planned to hold the first neuromatch in March. It was free, and 3,000 people attended.

In a point-of-view published in eLifein April, the organizers explain their strategies for running the online unconference. In May, they held neuromatch 2.0, also attended by about 3,000 people, and theyre planning neuromatch 3.0 for October. For the first time, at neuromatch 3.0, the organizers are charging a $25 registration fee that anyone can waive, no questions asked, and have opened the unconference to all neuroscientists, not just those interested in computational neuro.

Achakulvisut predicts that both online and in-person conferences will exist in the future, but that many neuromatch attendees will probably keep coming to online conferences. We have people from all over the world that typically cant show up if the conference is somewhere hard to get tobecause of visa restrictions, distance, expense, or something else.

The sort of reach that a conference like neuromatch offers is just the beginning of what Mike Morrison, a web developerturnedMichigan State University PhD student in work psychology, would like to see for science. In a commentary published September 3, he and his coauthors propose that scientific conferences, especially now that so many are taking place virtually, could be venues to update the whole world about the progress of science, not just the attendees.

Making all conference productstalks, posters, and abstractsavailable as YouTube videos, images via FigShare, and preprints, they argue, could be a way to accelerate the pace of discovery by reaching everyone who might possibly contribute. Conference administrators want this bigger impact for their attendees, Morrison says. Im really looking forward to hearing from a scientific conference to see if they want to try it.

Another democratizing strategy Morrison and colleagues propose is the #TwitterPoster, a threetofiveslide PowerPoint presentation optimized to be shared as a GIF on Twittera tool that could also work in poster sessions at virtual meetings. Sharing information in this flipbook-like style was so successful for a group of psychology grad students at University College Dublin earlier this year that their hashtag #GIFsFromYourGaff started trending.

Michigan State University PhD student Mike Morrison introduces the #TwitterPoster, a strategy for sharing science quickly on Twitter.

MIKE MOrrison

On the internet, it is the nature of content to be freely available, spread widely, and permanent, Morrison tells The Scientist. In science, our content is still locked-down, kept to ourselves, andespecially in the case of conference contentephemeral. What I want for the future is for science to close the gap with modern publishing methods, so it can be as available and easy to access as the rest of humanitys content.

The Transforming Vaccinology meeting originally planned for March was canceled, but the organizers and facilitating nonprofit Keystone Symposia regrouped to offer a COVID-19specific vaccinology conference online in June. In the context of a pandemic, it was perhaps even more critical to have so many researchersincluding keynote speaker Anthony Fauci, director of the National Institute of Allergy and Infectious Diseasesable to come together and trade ideas.

The meeting got tremendous interest, and a lot of unpublished data was shared, says Thale Jarvis, Keystone Symposias chief scientific officer. The organizers commented on the amazing . . . democratization of the access to science.

Participants from more than 60 countries engaged in extensive Q&A sessions with speakers via chat and video, and session moderators moved unanswered questions over to the public forum for further discussion. We have a variety of different ways that we try to try to connect people and, obviously, its never going to quite replicate those random interactions that happen at a face-to-face meeting, where you strike up a conversation on the way over to breakfast and end up discovering you have something in common scientifically, she says, but the sort of kneejerk reaction that because its a virtual format it wont give a satisfying outcome is a bit unfair.

Especially for innovators, being physically close at some point is, as far as the research indicates, pretty important.

Maria Roche, Harvard Business School

Since early in the pandemic, Gautam Dey, a postdoc at University College London, has co-organized an online seminar series called pombeTalks that draws around 150 fission yeast researchers to Zoom every other week. He and organizers of other virtual seminar series published a perspective in the Journal of Cell Science on August 1, giving tips for starting and supporting such a community.

The online formats, whether its a virtual conference format or a seminar series format, are extremely good at broadly disseminating information . . . and to make that as inclusive and effectively carbon neutral as possible, he says. But the thing that I anecdotally observe in those interactions is that they are, with some exceptions, built upon preexisting, real-world relationships between people that have built up over years, he adds. To me, it seems very difficult to de novo generate new scientific connections between people through these virtual formats, whatever they are.

Deys concern is neither uncommon nor unfounded. Maria Roche, who studies knowledge production and innovation at Harvard Business School, tells The Scientist that studies have shown that colocationeven temporary colocation at an in-person conferencecan have an effect on the rate and quality of scientific collaborations. Especially for innovators, being physically close at some point is, as far as the research indicates, pretty important, she says.

Psychologist Anne Frenzel and chronobiologist Martha Merrow, both of Ludwig Maximilian University of Munich, have collaborated to study participant experiences in virtual conferences created to reduce carbon emissions. In the first iteration, some participants gathered at regional hubs to cut down on travel and others participated fully online.

The researchers have been exploring whether conference participants experience different levels of subjective satisfaction of the three basic psychological needs of relatedness (feeling connected with the other conference attendees), competence (feeling capable, effective, and proficient), and autonomy (having a sense of choice) when attending virtual versus live conferences, Frenzel writes in an email to The Scientist.The relatedness factor seems the one which is most at stake with virtual formats.

According to Frenzel, preliminary and poorly statistically powered analyses so far indicate that virtual attendance, as compared to live attendance at the hubs, did not substantially affect psychological experiences of basic need satisfaction. But she cautions that she is reluctant to interpret those findings in a way that suggests virtual conferences work just as well as live conferences from a psychological perspective. Psychological research addressing the impact of digitally-based versus in-person interaction is fairly limited, she adds, but this striking research gap . . . is certainly currently being addressed in many ongoing projects inspired by the COVID crisis.

See more here:
COVID-19 Ushers in the Future of Conferences - The Scientist

Higher Antioxidant Levels Linked to Protection Against Glaucoma – Technology Networks

A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma. Their findings are published online in theJournal of Clinical Medicine, available here.

In general, glaucoma patients are vulnerable to increased intraocular pressure. However, a particular group of patients has no glaucomatous neurodegeneration despite high intraocular pressure -- patients with ocular hypertension.

The paper reports the discovery of a new mechanism to explain why patients with ocular hypertension do not have glaucoma. This is the first study evaluating oxidative stress and antioxidative agents in patients with normal-tension glaucoma and ocular hypertension during oxygen stress.

According to the American Academy of Ophthalmology, ocular hypertension is when the pressure inside the eye (intraocular pressure or IOP) is higher than normal.

The authors found that patients with ocular hypertension have increased antioxidant capacity and higher levels of anti-inflammatory, omega-3 derived chemical messengers involved in sustaining cell function in their plasma compared to patients with normal-tension glaucoma and age-matched controls. The abundance of these omega-3 fatty acid chemical messengers provides antioxidant defense, and as a consequence, potential resistance to elevated intraocular pressure and glaucomatous neurodegeneration by eliminating increases in systemic oxidative stress.

"The study opens avenues of therapeutic exploration highlighting the significance of the omega-3 fatty acid chemical messengers' antioxidant capacity as a potential diagnostic biomarker and as a novel treatment to prevent glaucomatous neurodegeneration," notes Dr. Nicolas G. Bazan, Boyd Professor, Ernest C. and Ivette C. Villere Chair of Retinal Degeneration, and Director of the Neuroscience Center of Excellence at LSU Health New Orleans School of Medicine.

Glaucoma is the most common cause of irreversible blindness. The sight-threatening disease is defined by a progressive loss of the innermost retinal neurons with corresponding visual field losses. Despite current treatments to lower the intraocular pressure, 15% of glaucoma patients go blind, and as many as 42% will lose sight in one eye.

Reference:

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Here is the original post:
Higher Antioxidant Levels Linked to Protection Against Glaucoma - Technology Networks